These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27586799)

  • 21. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.
    Psarras A; Emery P; Vital EM
    Rheumatology (Oxford); 2017 Oct; 56(10):1662-1675. PubMed ID: 28122959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
    Jiang J; Zhao M; Chang C; Wu H; Lu Q
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):248-272. PubMed ID: 32557263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IFN-α production by plasmacytoid dendritic cell associations with polymorphisms in gene loci related to autoimmune and inflammatory diseases.
    Berggren O; Alexsson A; Morris DL; Tandre K; Weber G; Vyse TJ; Syvänen AC; Rönnblom L; Eloranta ML
    Hum Mol Genet; 2015 Jun; 24(12):3571-81. PubMed ID: 25779693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting interferons in systemic lupus erythematosus: current and future prospects.
    Mathian A; Hie M; Cohen-Aubart F; Amoura Z
    Drugs; 2015 May; 75(8):835-46. PubMed ID: 25940912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases.
    De Ceuninck F; Duguet F; Aussy A; Laigle L; Moingeon P
    Drug Discov Today; 2021 Oct; 26(10):2465-2473. PubMed ID: 34224903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type I IFN system in the development and manifestations of SLE.
    Elkon KB; Wiedeman A
    Curr Opin Rheumatol; 2012 Sep; 24(5):499-505. PubMed ID: 22832823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microglia-dependent synapse loss in type I interferon-mediated lupus.
    Bialas AR; Presumey J; Das A; van der Poel CE; Lapchak PH; Mesin L; Victora G; Tsokos GC; Mawrin C; Herbst R; Carroll MC
    Nature; 2017 Jun; 546(7659):539-543. PubMed ID: 28614301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I Interferons in Autoimmune Disease.
    Crow MK; Olferiev M; Kirou KA
    Annu Rev Pathol; 2019 Jan; 14():369-393. PubMed ID: 30332560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An etiopathogenic role for the type I IFN system in SLE.
    Rönnblom L; Alm GV
    Trends Immunol; 2001 Aug; 22(8):427-31. PubMed ID: 11473831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I interferons (alpha/beta) in immunity and autoimmunity.
    Theofilopoulos AN; Baccala R; Beutler B; Kono DH
    Annu Rev Immunol; 2005; 23():307-36. PubMed ID: 15771573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-17: a new actor in IFN-driven systemic autoimmune diseases.
    Ambrosi A; Espinosa A; Wahren-Herlenius M
    Eur J Immunol; 2012 Sep; 42(9):2274-84. PubMed ID: 22949326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A compass that points to lupus: genetic studies on type I interferon pathway.
    Kyogoku C; Tsuchiya N
    Genes Immun; 2007 Sep; 8(6):445-55. PubMed ID: 17581625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-regulation of TNF and IFN-alpha in autoimmune diseases.
    Palucka AK; Blanck JP; Bennett L; Pascual V; Banchereau J
    Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3372-7. PubMed ID: 15728381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Interferon alpha antibodies show no cross reactions with typical autoantibodies].
    Görg S; Klouche M; Wilhelm D; Kirchner H
    Immun Infekt; 1993 Apr; 21 Suppl 1():54-6. PubMed ID: 8344695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology.
    Santana-de Anda K; Gómez-Martín D; Díaz-Zamudio M; Alcocer-Varela J
    Autoimmun Rev; 2011 Dec; 11(2):98-103. PubMed ID: 21872684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.
    Kim JM; Park SH; Kim HY; Kwok SK
    Int J Mol Sci; 2015 Jun; 16(6):14158-70. PubMed ID: 26110387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.